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Abstract
In a healthy body, ROS (reactive oxygen species) and antioxidants remain in balance. When the balance is
disrupted towards an overabundance of ROS, oxidative stress (OS) occurs. OS influences the entire reproductive
lifespan of a woman and even thereafter (i.e. menopause). OS results from an imbalance between prooxidants
(free radical species) and the body's scavenging ability (antioxidants). ROS are a double-edged sword – they serve
as key signal molecules in physiological processes but also have a role in pathological processes involving the
female reproductive tract. ROS affect multiple physiological processes from oocyte maturation to fertilization,
embryo development and pregnancy. It has been suggested that OS modulates the age-related decline in fertility.
It plays a role during pregnancy and normal parturition and in initiation of preterm labor. Most ovarian cancers
appear in the surface epithelium, and repetitive ovulation has been thought to be a causative factor. Ovulation-
induced oxidative base damage and damage to DNA of the ovarian epithelium can be prevented by antioxidants.
There is growing literature on the effects of OS in female reproduction with involvement in the pathophsiology
of preeclampsia, hydatidiform mole, free radical-induced birth defects and other situations such as abortions.
Numerous studies have shown that OS plays a role in the pathoysiology of infertility and assisted fertility. There
is some evidence of its role in endometriosis, tubal and peritoneal factor infertility and unexplained infertility. This
article reviews the role OS plays in normal cycling ovaries, follicular development and cyclical endometrial
changes. It also discusses OS-related female infertility and how it influences the outcomes of assisted reproductive
techniques. The review comprehensively explores the literature for evidence of the role of oxidative stress in
conditions such as abortions, preeclampsia, hydatidiform mole, fetal embryopathies, preterm labour and
preeclampsia and gestational diabetes. The review also addresses the growing literature on the role of nitric oxide
species in female reproduction. The involvement of nitric oxide species in regulation of endometrial and ovarian
function, etiopathogenesis of endometriosis, and maintenance of uterine quiescence, initiation of labour and
ripening of cervix at parturition is discussed. Complex interplay between cytokines and oxidative stress in the
etiology of female reproductive disorders is discussed. Oxidant status of the cell modulates angiogenesis, which
is critical for follicular growth, corpus luteum formation endometrial differentiation and embryonic growth is also
highlighted in the review. Strategies to overcome oxidative stress and enhance fertility, both natural and assisted
are delineated. Early interventions being investigated for prevention of preeclampsia are enumerated. Trials
investigating combination intervention strategy of vitamin E and vitamin C supplementation in preventing
preeclampsia are highlighted. Antioxidants are powerful and there are few trials investigating antioxidant
supplementation in female reproduction. However, before clinicians recommend antioxidants, randomized
controlled trials with sufficient power are necessary to prove the efficacy of antioxidant supplementation in
disorders of female reproduction. Serial measurement of oxidative stress biomarkers in longitudinal studies may
help delineate the etiology of some of the diosorders in female reproduction such as preeclampsia.
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Review
1. Oxidative Stress
1.1 Free radicals
Free radical species are unstable and highly reactive. They
become stable by acquiring electrons from nucleic acids,
lipids, proteins, carbohydrates or any nearby molecule
causing a cascade of chain reactions resulting in cellular
damage and disease [1-4], figure 1) . There are two major
types of free radical species: reactive oxygen species (ROS)
and reactive nitrogen species (NOS).
1.2 Reactive oxygen species
The three major types of ROS are: superoxide (O2
•-),
hydrogen peroxide (H2O2), hydroxyl (OH•). The superox-
ide radical is formed when electrons leak from the elec-
tron transport chain [5]. The dismutation of superoxide
results in the formation of hydrogen peroxide. The
hydroxyl ion is highly reactive and can modify purines
and pyrimidines and cause strand breaks resulting in DNA
damage [6]. Some oxidase enzymes can directly generate
the hydrogen peroxide radical.
ROS have been implicated in more than 100 diseases [7-
10]. They have a physiological and pathological role in
the female reproductive tract. Numerous animal and
human studies have demonstrated the presence of ROS in
the female reproductive tract: ovaries, [11-15], fallopian
tubes [16] and embryos [17]. ROS is involved in the mod-
ulation of an entire spectrum of physiological reproduc-
tive functions such as oocyte maturation, ovarian
steroidogenesis, corpus luteal function and luteolysis
[11,12,18]. ROS-related female fertility disorders may
have common etiopathogenic mechanisms. ROS may
also originate from embryo metabolism and from its
surroundings.
1.3 Reactive nitrogen species
Nitric oxide (NO) is synthesized during the enzymatic
conversion of L-arginine to L-citrulline by nitric oxide syn-
thase (NOS) [19-21]. With an unpaired electron, NO,
which is a highly reactive free radical, damages proteins,
carbohydrates, nucleotides and lipids and, together with
other inflammatory mediators, results in cell and tissue
damage, low-grade, sterile inflammation and adhesions
[20]. NO potently relaxes arterial and venous smooth
muscles and, less strongly, inhibits platelet aggregation
and adhesion. NO donors, acting as vasodilating agents,
are therefore a possible therapeutic approach [22]. NO
acts in a variety of tissues to regulate a diverse range of
physiological processes, but excess of NO can be toxic
[1,20,21,23].
Reactive nitrogen species have been associated with
asthma, ischemic/reperfusion injury, septic shock and
atherosclerosis [24-27]. The two common examples of
reactive nitrogen species are nitric oxide (NO) and nitro-
gen dioxide [1,3]. NO is produced by the enzyme NO syn-
thase. There are 3 types of nitric oxide synthase (NOS)
isoenzymes in mammals involving endothelial NO syn-
thase (NO synthase 3), neuronal NO synthase (NO syn-
thase 1) and inducible NO synthase (NO synthase 2).
Neuronal NO synthase (nNOS) and endothelial NO syn-
thase (eNOS) are constitutive NO synthases, and respon-
sible for the continuous basal release of NO. Inducible
NO synthase (iNOS) is present in mononuclear phago-
cytes (monocytes and macrophages) and produces a large
amount of NO. This is expressed in response to proin-
flammatory cytokines and lipopolysaccharides
[21,23,28]. Inducible NO synthase is activated by
cytokines such as, interleukin-1, and TNF-α and lipopoly-
saccharides. Endothelial NO synthase is expressed in the-
cal cells, granulosa cells, and the surface of oocyte during
the follicular development. In pathological conditions,
inducible NO synthase might play a major role in NO
production. In most organs, inducible NO synthase is
expressed only in response to immunological stimuli
[29].
1.4 Antioxidants
Under normal conditions, scavenging molecules known
as antioxidants convert ROS to H2O to prevent overpro-
duction of ROS. There are two types of antioxidants in the
human body: enzymatic antioxidants and non-enzymatic
antioxidants [1,3].
1.5 Enzymatic antioxidants
Enzymatic antioxidants are also known as natural antioxi-
dants, they neutralize excessive ROS and prevent it from
damaging the cellular structure. Enzymatic antioxidants
are composed of superoxide dismutase, catalase, glutath-
ione peroxidase and glutathione reductase, which also
causes reduction of hydrogen peroxide to water and
alcohol.
1.6 Non-enzymatic antioxidants
Non-enzymatic antioxidants are also known as synthetic
antioxidants or dietary supplements. The body's complex
antioxidant system is influenced by dietary intake of anti-
oxidant vitamins and minerals such as vitamin C, vitamin
E, selenium, zinc, taurine, hypotaurine, glutathione, beta
carotene, and carotene [1-3,30]. Vitamin C is a chain
breaking antioxidant that stops the propagation of the
peroxidative process. Vitamin C also helps recycle oxi-
dized vitamin E and glutathione [31]. Taurine, hypotau-
rine and transferrin are mainly found in the tubal and
follicular fluid where they protect the embryo from OS
[17]. Glutathione is present in the oocyte and tubal fluid
and has a role in improving the development of the zygote
beyond the 2-cell block to the morula or the blastocyst
stage [32].Reproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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Mechanisms of oxidative stress-induced cell damage Figure 1
Mechanisms of oxidative stress-induced cell damage.Reproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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1.7. Oxidative stress in female reproduction
Cells have developed a wide range of antioxidants systems
to limit production of ROS, inactivate them and repair cell
damage [1-3,33]. OS influences the entire reproductive
span of women's life and even thereafter (i.e. meno-
pause). It has been suggested that the age-related decline
in fertility is modulated by OS [34]. It plays a role during
pregnancy [35] and normal parturition [36,37] and in ini-
tiation of preterm labor [38,39]. The pathological effects
are exerted by various mechanisms including lipid dam-
age, inhibition of protein synthesis, and depletion of ATP
[40]. There is some understanding of how ROS affect a
variety of physiologic functions (i.e. oocyte maturation,
ovarian steroidogenesis, ovulation, implantation, forma-
tion of blastocyst, luteolysis and luteal maintenance in
pregnancy) [14,15,18,19,41].
ROS are a double-edged sword – they serve as key signal
molecules in physiological processes but also have a role
in pathological processes involving the female reproduc-
tive tract. Since the balance is maintained by the presence
of adequate amounts of antioxidants, measuring levels of
the antioxidants, individually or as total antioxidant
capacity (TAC), has also been examined [15,18,42,43].
Superoxide dismutase (SOD) enzymes, Copper-Zinc SOD
(Cu-Zn SOD) and Manganese superoxide dismutase
(MnSoD) have been localized in the granulose and thecal
cells of the growing follicle. Selenium dependent glutath-
ione peroxidase activity has been demonstrated in the fol-
licular fluid and serum of patients undergoing IVF. The
expression profiles of the transcripts of the antioxidant
enzymes such as superoxide dismutase, glutathione per-
oxidase and gamma-glutamylcysteine synthetase in both
human and mouse oviducts and oocytes have also been
examined [16]. There is growing literature on the effects of
OS in the female reproduction with involvement in the
pathophsiology of pre-eclampsia [44,45], hydatidiform
mole [46-48], free radical-induced birth defects [49] and
other situations such as abortions [50].
1.8 Measurement of oxidative stress
The presence of ROS and antioxidants in the female repro-
ductive tract has been demonstrated by various methodol-
ogies in animal and human studies. A number of OS
biomarkers have been investigated including superoxide
dismutase, glutathione peroxidase, conjugated dienes,
lipid peroxides, thiobarbituric acid reactive substances,
glutaredoxin, oxidative DNA adducts, follicular fluid, NO
and TAC [12,15,16,19,29,42,51-58] (Table 1).
Metabolites of NO (nitrite and nitrate) in peritoneal fluid
are determined by nitrate reductase and the Griess reac-
tion [20,23]. Total NO (nitrite and nitrate) levels in the
serum and follicular fluid assay of NO are measured via a
rapid-response chemiluminescence analyzer [29]. Various
biomarkers of oxidative stress have been determined in
the placenta by immunohistochemistry or western blot
analysis (Table 2). Oxidative DNA adducts 8-hydroxy 2-
deoxyguanosine-have been studied by immunostaining
in placenta [45], in patients with IUGR (intrauterine
growth retardation) and patients with preeclampsia and
IUGR [45]. The basal levels of ROS in the leukocytes in
whole blood can be determined using the dihydroethid-
ium and dichlorodihydrofluorescein-diacetate probes
(Table 2).
2. Oxidative Stress & Female Infertility
Infertility is a disease defined as "the inability to conceive
following 12 or more months of unprotected sex before
an investigation is undertaken unless the medical history
and physical findings dictate earlier evaluation and and
treatment [67]. The prevalence of female infertility ranges
from 7% to 28%, depending on the age of the woman. In
general, an estimated 84% of couples conceive after 1 year
of intercourse, and 92% of the couples conceive after 2
years [68]. Although the frequency and origin of different
forms of infertility varies, 40%–50% of the etiology of
infertility studied is due to female causes [69].
Table 1: Oxidative stress biomarkers in female reproductive tract
Study Biomarker Methodology Measurement units
Sugino et al [41] Enzymatic antioxidants: Cu SOD, 
Mn SOD, catalase, glutathione 
peroxidase
Reverse transcription-polymerase 
chain reaction
cDNA sequences
Attaran et al [4] Total antioxidant capacity Enhanced chemiluminescence 
assay
Trolox equivalents
Jozwik et al [15] Lipid peroxides; Malondialdehyde, 
conjugated dienes, Thiobarbituric 
acid reactive substances.
Thiobarbituric acid method Micromole of malondialdehyde/L
Seino et al [52]. Oxidative DNA adducts 8-hydroxy 2-deoxyguanosine Immunocytochemical stainingReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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A primary diagnosis of male factor infertility is made in
30% of infertile couples. Combined female and male fac-
tor infertility is responsible for 20%–30% of cases.
Finally, unexplained infertility affects 15% of couples
[70]. If the results of a standard infertility examination are
normal, a diagnosis of unexplained or idiopathic infertil-
ity is assigned [70]. Data from the National Survey for
Family Growth indicate that the number of women with
impaired fecundity has increased from 1982 to 1995, an
increase of 35% in the number of women. Approximately
1.3 million American couples receive medical advice or
treatment for infertility every year [71]. OS has a role in
etiopathogenesis of endometriosis, tubal factor infertility,
and unexplained infertility. Impact of OS on ART is dis-
cussed in further sections.
2.1 Pathophysiology of oxidative stress in female reproduction
Oxygen toxicity is an inherent challenge to aerobic life
[72]. ROS can modulate cellular functions, and OS can
impair the intracellular milieu resulting in diseased cells
or endangered cell survival. The role of ROS in various dis-
eases of the female reproductive tract has been investi-
gated. ROS can affect a variety of physiological functions
in the reproductive tract, and excessive levels can result in
precipitous pathologies affecting female reproduction.
The oxidant status can influence early embryo develop-
ment by modifying the key transcription factors and
hence modifying gene expression [73]. Concentrations of
ROS may also play a major role both in the implantation
and fertilization of eggs [72]. There is an increased interest
to examine the role of OS in female reproduction because
it may be a major link in the infertility puzzle as well as in
some reproductive organ diseases such as endometriosis.
Recently, OS has been reported to have an important role
in the normal functioning of the female reproductive sys-
tem and in the pathogenesis of female infertility [33,74].
2.2 Cytokines, oxidative stress and female reproduction
The control of ovarian stromal cells and germ cell func-
tion is a diverse paradigm and oxidative stress may be one
of the modulators of ovarian germ cell and stromal cell
physiology. A number of autocrine and paracrine factors
affect the modulation of various ovarian functions and
steroidogenesis. Cytokines are polypeptides or glycopro-
teins secreted into the extra cellular compartment by the
leukocytes [75]. Mammalian ovulation or follicular rup-
ture was proposed to result from the vascular changes and
the proteolytic cascade [54]. The cross talk between these
two cascades is mediated by cytokines, vascular endothe-
lial growth factor (VEGF), and ROS (both reactive nitro-
gen and oxygen radicals). Interleukin-1β causes nitrite to
accumulate in rat ovarian dispersates, demonstrating the
close interaction between cytokines and NOS [76]. OS
and cytokines are proposed to be interlinked and act as
intercellular and intracellular messengers in the ovary. A
Table 2: Measurement of biomarkers of oxidative stress in pregnancy
Study Biomarkers Methodology Measurement units
Jauniaux et al [59] Immunohistochemistry Heat shock protein 70, 
hydroxynenal, nitrotyrosine 
residues.
Fluorescence intensity
Wang et al, Djordjevic et al [60, 61] Antioxidant enzyme activity assays Total SOD activity, catalase 
activity, glutathione peroxidase 
activity, reduced glutathione assay
Change in optical density/minutes/
mg protein
Wiktor et al [62] Oxidative DNA adducts 8-hydroxy-2 deoxyguanosine Micromoles/mole of 2-deoxy 
guanosine
Holthe et al [63] Superoxide anion, hydrogen 
peroxide and peroxynitrite
Dihydrethidium probe 
Dichlorodihydrofluorescein 
Dihydrorhodamine 123 
Spectrophotometry/flow 
cytometry
Nanomoles/10 min/106 cells
Ishihara et al [64] Lipid peroxidation products Isoprostane, Urinary 8-epi-
prostaglandin F2lpha, assayed by 
gas chromatography/mass 
spectrophotometer analysis
pg/mg of creatinine
Vaisanen-Tommiska et al [65] Nitric oxide; Greiss reaction Stable end products: nitrite/
nitrate
Fluorometric assay, results 
expressed as NOx (sum of 
converted nitrite and very small 
amount of nitrite in serum).
Buhimishi et al [66] Plasma and red blood cell 
glutathione content
Colorimetric assay Nanomoles/mgm of haemoglobinReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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number of investigators have investigated the synthesis of
NOS and ROS in the ovaries [21,55,58].
Defective placentation leads to placental hypoxia and
reperfusion injury due to ischemia and the resultant OS
triggers the release of cytokines and prostaglandins, which
results in endothelial cell dysfunction and plays an impor-
tant role in the development of pre-eclampsia [77,78].
TNF-α a plasma cytokine, has been demonstrated to cause
the endothelial cell injury [79]. A link between OS and
expression of cytokine receptors in the cytotrophoblast,
vascular smooth muscle cells and endometrial cells has
also been proposed, further establishing that hyperactiva-
tion of ROS may result in pre-eclampsia [80].
The activation of mononuclear phagocytes can be trig-
gered in endometriosis by a number of factors including
damaged red blood cells and the apoptotic endometrial
cells. A positive correlation between concentrations of
tumor necrosis factor (TNF)-α in the peritoneal fluid and
endometriosis has been reported [75]. Cytokines released
by the macrophages influence the redox status of the
ectopic endometrium in patients with endometriosis [81].
Superoxide dismutase, glutathione peroxidase activity
and lipid peroxidation levels were measured in ectopic
endometrial tissue obtained from ovarian endometrio-
mas. Superoxide dismutase activity was found to be signif-
icantly higher in the ectopic endometrium than in eutopic
endometrium, and a positive correlation was seen
between malondialdehyde levels and plasma 17-beta
estradiol levels. TNF-α has been shown to cause up regu-
lation of expression of Manganese (Mn) superoxide dis-
mutase in the endometrium in vitro [82]. The antioxidant
MnSOD neutralizes superoxide anions generated by
cytokine TNF-α. This is a self protective mechanism
against TNF-α induced oxidative stress. Estrogen and pro-
gesterone withdrawal leads to stimulation of prostaglan-
din F2α production via ROS-induced NFkappa β
activation [83]. The mechanism of menstruation is
unclear, and activation of the transcription factor NFka-
ppa β may be a piece in the puzzle.
Ovarian epithelial cancer is the most common type of
ovarian cancer. Ovarian epithelial inflammation has been
suggested as an etiological factor in ovarian epithelial can-
cer [11,84]. The mechanisms that bring about follicular
rupture result in the exposure of the ovarian surface epi-
thelial cells to deleterious agents (e.g. free radicals and
TNF-α) [85,86]. Thus, incessant ovulation and its com-
plex articulation by OS, inflammation and cytokines
repeated cyclically may be involved in the etiopathogene-
sis of ovarian cancer [86]. Factors that inhibit ovulation
such as oral contraceptives reduce the risk of epithelial
ovarian cancer [87,88]. Recent studies point towards a
role of genes active in the process of metabolism of oxida-
tion products, in the etiology of ovarian cancer [89].
2.3 Reactive oxygen species and mediators of angiogenesis
Angiogenesis is a pathophysiological process involving
formation of blood vessels from preexisting vessels. The
induction of angiogenesis occurs when there is a defi-
ciency of oxygen in tissues. This process of neovasculariza-
tion results from hypoxia and induction of various
angiogenic factors, and it has a role to play in physiologi-
cal processes such as follicular development, endometrial
growth, embryo development, growth of placental vessels
and wound repair [90,91]. Angiogenesis is important for
cyclical regeneration of endometrium in the menstrual
cycle. A complex cytokine influence at the maternal-fetal
interface creates the conditions that are necessary to sup-
port embryo implantation in the endometrium [92,93].
Any imbalance between the cytokines and angiogenesis
factors could result in implantation failure and pregnancy
loss [94]. Critical changes occur in the vascular system,
and these changes accompany follicular growth. Follicular
growth, selection of dominant follicle, corpus luteum for-
mation, endometrial differentiation and embryo forma-
tion are key processes dependent on neovascularization
[90,95]. As the endometrium grows in the menstrual
cycle, vessel regeneration occurs (i.e. spiral arterioles and
capillaries) [96]. Estrogens promote angiogenesis in the
endometrium by controlling the expression of factors
such as VEGF [97]. ROS generated from NADP (H) oxi-
dase is critical for VEGF signaling in vitro and angiogen-
esis in vivo [98]. Small amounts of ROS are produced
from endothelial NADP (H) oxidase activated by growth
factors and cytokines.
ROS that are generated in and around the vascular
endothelium may play a role in normal cellular signaling
mechanisms. They may also be an important causative
factors in endothelial dysfunction that leads to the devel-
opment of atherosclerosis, diabetes complications and
ischemia perfusion injury [98,99]. The molecular mecha-
nism by which the oxidant status of cells modulates ang-
iogenesis is not completely understood. As our
understanding the role ROS-induced angiogenesis plays
in atherosclerosis and myocardial angiogenesis grows,
future studies should investigate the role ROS plays in the
angiogenesis in the female reproductive tract.
2.4 Reactive oxygen species and the endometrium
There is a cyclical variation in the expression of superoxide
dismutase (SOD) in the endometrium. SOD activity
decreases in the late secretory phase while ROS levels
increase [100]. These changes have been hypothesized to
be important in the genesis of menstruation and endome-
trial shedding. The levels of prostaglandin F2 α increase
towards the late secretory phase and ROS triggers theReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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release of prostaglandin F2 α in vitro [101]. Stimulation
of the cyclooxygenase enzyme is brought about by ROS
via activation of the transcription factor NFKappa β, sug-
gesting a mechanism for menstruation [83].
2.5 ROS and endometriosis
Increased generation of ROS by activated peritoneal mac-
rophages has been reported in the peritoneal fluid [102].
Conflicting results were reported in further studies with
large patient numbers, which failed to demonstrate an
antioxidant or oxidant balance [74,103]. ROS levels in
peritoneal fluid of patients with endometriosis were not
significantly higher than controls.
An increased titer of autoantibodies related to OS has
been reported in women with endometriosis resulting in
an increase in serum autoantibody titers to oxidatively
modified low density lipoproteins [104]. An OS-induced
increase in autoantibody titers in the peritoneal fluid has
been demonstrated in women with endometriosis. Ele-
vated levels of the marker of lipid peroxidation lyso-
phophatidyl choline, a potent chemotactic factor for
monocytes/T-lymphocytes, were seen in the peritoneal
fluid of women with endometriosis [105]. Non-terminal
oxidation may have a role in the pathophysiology of
endometriosis. Minimally oxidized low density lipopro-
tein (LDL) (M-LDL) is present in peritoneal fluid of
women with endometriosis in place of the terminally oxi-
dized LDL (Ox-LDL) [106]. The ratio of lysophosphatidyl
choline, a breakdown product of Ox-LDL, to phosphati-
dyl choline suggests M-LDL rather than Ox-LDL. Modest
levels of OS induced proliferation of endometrial stromal
cells in vitro, was inhibited by antioxidants [107]. RU486,
a potent antiprogestational agent with antioxidant activity
also decreased proliferation of epithelial and stromal cells
[108].
2.6 Reactive oxygen species and the ovary
Markers of oxidative stress such as superoxide dismutase,
Cu-Zn superoxide dismutase, Mn superoxide dismutase,
glutathione peroxidase, γ glutamyl synthetase and lipid
peroxides have been investigated by immunohistochemi-
cal localization, m-RNA expression and thiobarbituric
acid method [4,14,41]. The expression of various biomar-
kers of OS has been demonstrated in normal cycling
human ovaries [13,14]. All follicular stages have been
examined for SOD expression including primordial, pri-
mary, preantral and nondominant antral follicles in follic-
ular phase, dominant follicles and atretic follicles [14].
ROS may have a regulatory role in oocyte maturation, fol-
liculogenesis, ovarian steroidogenesis and luteolysis.
There is a delicate balance between ROS and antioxidant
enzymes in the ovarian tissues. The antioxidant enzymes
neutralize ROS production and protect the oocyte and
embryo.
The presence of superoxide dismutase in the ovary,
revealed intense staining by immunohistochemistry in
the theca interna cells in the antral follicles [13]. Antibody
to Ad4-binding protein (Ad4BP) was utilized to localize
Ad4BP in the nuclei of theca and granulosa cells. Ad4BP is
a steroidogenic transcription factor that induces transcrip-
tion of the steroidogenic P450 enzyme. Thus, it controls
steroidogenesis in the ovaries. The correlation between
Ad4BP and superoxide dismutase expression suggests an
association between OS and ovarian steroidogeneis [14].
Both human granulosa and luteal cells respond to hydro-
gen peroxide with an extirpation of gonadotropin action
and inhibition of progesterone secretion [11]. The pro-
duction of both progesterone and estradiol hormones is
reduced when hydrogen peroxide is added to a culture of
human chorionic gonadotropin-stimulated luteal cells.
Hydrogen peroxide lowers both cAMP dependent and
non-cAMP dependent steroidogenesis [109]. The role of
hCG (human chorionic gonadotropin) in the expression
of the antioxidant enzyme superoxide dismutase (SOD)
has been investigated. Corpora lutea collected from
patients at hysterectomy and surgery for ectopic preg-
nancy were studied [14]. The Cu-Zn SOD expression in
the corpora lutea paralleled levels of progesterone and
these levels rose from early to mid luteal phase and
decreased during the regression of the corpus luteum.
However, in the corpus luteum from pregnant patients,
the mRNA expression for Cu-Zn superoxide dismutase
was significantly higher than that in midcycle corpora
lutea. This enhanced expression of luteal Cu-Zn SOD may
be due to hCG and hCG may have an important role in
maintenance of corpus luteal function in pregnancy.
Levels of three oxidative stress biomarkers, conjugated
dienes, lipid hydroperoxide and thiobarabituric acid were
determined in preovulatory follicles. Concentration gradi-
ent was found to exist as levels of all three markers were
significantly lower in the follicular fluid compared with
serum levels [15]. The preovulatory follicle has a potent
antioxidant defense, which is depleted by the intense per-
oxidation [15]. Glutathione peroxidase may also main-
tain low levels of hydroperoxides inside the follicle and
thus play an important role in gametogenesis and fertili-
zation [42].
2.7 Nitric Oxide synthase in female reproduction
The production of a viable oocyte is modulated by a com-
plex interaction of endocrine, paracrine and autocrine fac-
tors leading to follicular maturation, granulosa cell
maturation, ovulation and luteinization. Many hormonal
and paracrine factors determine oocyte competence and
embryo quality. Steroid hormones and local autocrine
and paracrine factors influence ovarian stromal cells. The
gonadotropins act through complex, multiple localReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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signaling pathways. Cyclic AMP is thought to be the sec-
ond messenger to bring about the effect of luteinizing hor-
mone and follicular stimulating hormone [110]. In turn,
cyclic AMP may activate other signaling pathways. Cyclic
guanosine monophosphate (cGMP)-a cyclic nucleotide
has also been proposed as a second messenger pathway.
The effects of NO are proposed to be mediated through
cGMP as a second messenger or by generation of ROS
resulting from interaction of NO with superoxide radicals
[111].
NO generated by macrophages in response to invading
microbes acts as an antimicrobial agent [21]. Neurons,
blood vessels and cells of the immune system are integral
parts of the reproductive organs, and in view of the impor-
tant functional role that NO plays in those systems, it is
highly likely that NO is an important regulator of the biol-
ogy and physiology of the reproductive system. NO has
established itself as a polyvalent molecule that plays a
decisive role in regulating multiple functions within the
female as well as male reproductive system [21]. As a final
immune effector, NO generated by inducible NO syn-
thase, kills pathogens and abnormal cells but may play a
detrimental role by damaging normal host tissue and
cells, especially when inducible NO synthase is persist-
ently expressed [20].
2.8 Nitric oxide synthase and fallopian tubes
The presence of NO synthase enzymes, both the constitu-
tive and the inducible forms was delineated by
immunhistochemistry and the presence of NADPH-dia-
phorase activity in human tubal cells [112,113]. The pro-
duction of NO was demonstrated by positive NADPH
diaphorase activity in the human fallopian tube. An
endogenous NO system exists in the fallopian tubes
[114]. NO has a relaxing effect on smooth muscles and it
has similar effects on tubular contractility. Deficiency of
NO may lead to tubal motility dysfunction, resulting in
retention of the ovum, delayed sperm transport and infer-
tility. Infertility associated with urogenital tract infections
is associated with diminished sperm motility and viabil-
ity. Increased NO levels in the fallopian tubes are
cytotoxic to the invading microbes and also may be toxic
to spermatozoa [114].
2.9 Nitric oxide synthase, endometrium, and myometrium
Expression of endothelial and inducible NO synthase
have been demonstrated in the human endometrium
[115], and the endometrial vessels [116]. Endothelial NO
synthase, originally identified in vascular endothelial
cells, is distributed in glandular surface epithelial cells in
the human endometrium. NO also regulates the microv-
asculature of the endometrium and is important in
menstruation.
Endothelial NOS like immunoreactivity has been
reported in the endothelial cells lining the vessels,
endometrium and endometrial glandular epithelial cells
and myometrium [117]. Inducible NOS like immunore-
activity was detected in decidualised stromal cells and also
expressed in tissues from first trimester of pregnancy.
Thus, NO has a role to play in decidualisation of the
endometrium and preparation of the endometrium for
implantation.
Highest levels of expression of endothelial NOS mRNA
have been reported in the late secretory phase of the
endometrium [115]. In addition, NO might participate in
the regulation of uterine contraction [118]. In normal fer-
tile woman, the contractions increase throughout the pro-
liferative and periovulatory phases, and decrease in the
secretory phase. From this point, NO is synergistic with
progesterone and might relax uterine contraction in the
secretory phase in a paracrine fashion. Nitric oxide regu-
lates the endometrial, myometrial and microvascular
functions in the uterus by paracrine functions. The effects
of the antiprogestational agent, Mifepristone on the
endothelial NOS expression in the endometrium were
investigated during the implantation phase [119]. Mife-
pristone inhibited the endometrial glandular epithelial
eNOS expression and did not affect the endothelilal
eNOS. The results supported the role of epithelial eNOS
in endometrial receptivity in the perimplantation period.
Significant increase in the levels of serum metabolites of
NOS amongst users of progestin only contraceptives has
been reported [120]. A positive correlation was also dem-
onstrated between NO levels and prolonged/heavy bleed-
ing. Thus NO may be involved in the pathophysiology of
menorrhagia.
NO plays a significant role in pregnancy and labor.
Expression of inducible NOS was highest in patients with
preterm pregnancy and not in patients in term labor. The
expression of these enzymes decreased by 75% at term
and was barely detectable in preterm in labor patients or
term labor patients [121] reiterating that NO has a role in
maintenance of uterine quiescence. However other
authors have reported conflicting results. Induction of
iNOS expression was demonstrated in fetal membranes in
labour and in in-vitro studies [122]. Higher NO
metabolite concentrations were demonstrated in amni-
otic fluid collected from women in labor than in non-
laboring patients, both at term (15.4 ± 1.6 vs. 6.8 ± 0.6
microM/mg creatinine) and preterm (16.7 ± 2.0 vs. 7.0 ±
0.8 microM/mg creatinine) [123].
2.10 Nitric oxide synthase and endometriosis
Endometriosis is found in about 35% of infertile women
who have laparoscopy as part of their infertility workup
[71]. Production of ROS by peritoneal fluid mononuclearReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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cells was reported to be associated with endometriosis
[75]. Low levels of NO are important in ovarian function
and implantation and cause relaxation of oviduct muscu-
lature [112]. High levels of NO are reported as having del-
eterious effects on sperm motility, toxic to embryos and
inhibit implantation [124,125]. In vitro fertilization, a
process that avoids contact of gametes and embryos with
potentially toxic peritoneal and oviductal factors associ-
ated with endometriosis (e.g., NOS, ROS) improves the
chances of conception in these women. NO is a free radi-
cal with deleterious effects and is an important bioregula-
tor of apoptosis [126]. Activation of polymorphonuclear
leucocytes and macrophages leads to increased produc-
tion of ROS [102]. Increase in number and activity of mac-
rophages is accompanied by release of more cytokines
and other immune mediators, such as NO. This was ini-
tially implicated in low-grade inflammation, while ele-
vated peritoneal NO is consistent with the increased
number and activity of macrophages [20]. High levels of
NO, such as those produced by macrophages, can nega-
tively influence fertility in several ways. Changes in perito-
neal fluid, an environment that hosts the process of
ovulation, gamete transportation, sperm oocyte interac-
tion, fertilization, and early embryonic development,
might affect all these steps of reproduction [2,20,127].
Studies investigating the association of nitric oxide levels
and lipid peroxides and reactive oxygen species in perito-
neal fluid did not find any significant difference in
patients with or without endometriosis [103,128,129]
Conflicting results were obtained in studies conducted by
Szczepanska et al [2]. The total antioxidant capacity
reduced and the individual antioxidant enzymes like
superoxide dismutase were significantly lower in the peri-
toneal fluid of women with endometriosis-associated
infertility. The lipid peroxide levels were the highest
amongst patients with endometriosis suggesting role of
ROS in the development of the disease process [2]. There
is a cyclical expression of mRNA of NOS in the epithelial
glands of the human endometrium. Higher amounts of
NO and NOS are seen in the endometrium of women
with endometriosis [28,130,131]. NOS expression in the
ectopic endometrium of patients with adenomyosis is
continuous throughout the menstrual cycle [132].
Peritoneal fluid NO levels, peritoneal macrophage NOS
activity, and peritoneal macrophage inducible NOS pro-
tein expression has been examined in women with
endometriosis-associated infertility. Peritoneal macro-
phages express higher levels of NOS, have higher NOS
enzyme activity, and produce more NO in response to
immune stimulation in vitro [23]. High levels of NO
adversely affect sperm, embryos, implantation, and ovi-
ductal function, indicating that reduction in the perito-
neal fluid NO production or blocking NO effects may
improve fertility in women with endometriosis [23].
However, generation of peroxynitrite by ectopic
endometrium has been reported in patients with adenom-
yosis. Expressions of endothelial and inducible NO syn-
thase and peroxynitrite generation was markedly reduced
after GnRH agonist therapy, supporting their potential
role in the pathophysiology of adenomyosis [132]. Serum
NO levels are suppressed by GnRH agonist and upregu-
lated by gonadotropin stimulation during controlled
ovarian stimulation in female partners from couples with
male factor infertility [133]. Maximal levels were meas-
ured at the time of ovulation in the same study. Elevated
NO production was not demonstrated in patients with
ovarian hyperstimulation.
Increased levels of NO were demonstrated in the perito-
neal fluid of patients with endometriosis [20,23]. It has
also been hypothesized that ROS may have a role in for-
mation of adhesions associated with endometriosis [134].
Patients with endometriosis show a higher 8-hydroxy 1-
deoxyguanosine index compared to patients with other
causes of infertility, such as tubal, male factor or idio-
pathic causes [52].
Expression of NOS is elevated in patients with endometri-
osis, and a common polymorphism of exon 7 at nucle-
otide 894 in the endothelial NOS gene may be associated
with endometriosis [135]. Hence variations in the expres-
sion of the eNOS gene may be involved in endometrial
angiogenesis and thus modulate the process of
endometriosis.
Expression of endothelial NO synthase in the
endometrium of patients with endometriosis or adenom-
yosis is persistently marked throughout the menstrual
cycle [132]. Many investigators have reported increased
expression of endothelial NOS in the glandular
endometrium in patients with endometriosis [28,130].
Inducible NOS isoform is elevated in tissues of patients
with endometriosis [131]. The endometrial development
affects embryo implantation, and inconsistent develop-
ment between endometrium and embryo could impede
embryo implantation. Nitric oxide affects fecundity in
endometriosis and adenomyosis [136]. Significant differ-
ences are seen in the uterine hyperperistalsis and
dysperistalsis in patients with endometriosis compared
with the control groups, and this may be responsible for
disturbed sperm transport and reduced fertility [137].
Various cytokines secreted from endometrial cells,
immune cells, or macrophages stimulate endothelial NO
synthase to release NO [3,28,136]. These abnormal
immune responses might eventually stimulate macro-
phages and/or endometrial cells to persistently produce a
large amount of NO and inhibit implantation [138].
Increased expression of endothelial NO synthase has beenReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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reported throughout the menstrual cycle in the
endometrium of women with endometriosis [139].
2.11 Nitric oxide synthase and the ovary
Ovarian follicullogenesis not only involves gonadotro-
pins and the steroids, but it also involves local autocrine
and paracrine factors. Nitric oxide radical is one of the
local factors involved in ovarian follicullogeneis and ster-
oidogenesis. Nitric oxide acts through activation of vari-
ous iron containing enzymes. It binds to the heme
containing enzyme guanylate cyclase, which activates the
cyclic nucleotide cyclic-GMP [110]. Plasma concentra-
tions of nitrate monitored during the follicular cycle, have
revealed peak levels at ovulation [133,140]. Nitric oxide
inhibits ovarian steroidogenesis [52]. The presence of
endothelial NO synthase in human corpora lutea and the
expression has been reported in the mid and early luteal
phase and to a lesser extent in the late luteal [53]. Nitric
oxide inhibits steroidogenesis in the corpus luteum and
has luteolytic action mediated through increased prostag-
landins and by apoptosis [53,141].
Follicular fluid NO seems to be produced by either
endothelial NO synthase or induced NO synthase. How-
ever, in the normal physiological conditions follicular
fluid NO seems to be synthesized from granulosa cells by
endothelial NO synthase, since in isolated human follicu-
lar cells at least 90% of cells are granulosa cells even
though macrophages and lymphocytes are present as well.
In patients undergoing IVF, a positive correlation was
determined between follicular fluid nitrate/nitrite levels
and the follicular volume as well as the serum estradiol
concentration [142]. In contrast to these findings, Manau
et al, found no association between follicular fluid nitrite/
nitrate levels and parameters of ovarian response [143].
Biomarkers like serum nitric oxide measurements cannot
be used as predicting success with IVF [143,144]. Serum
nitrate concentration may not be a good biomarker
because of the short half-life of NO. Follicular blood flow
was found to be a better prognostic factor for predicting
successful outcomes with IVF than follicular NO levels
[138]. Follicular fluid NO levels were altered in patients
with infertility associated diseases. NO follicular fluid lev-
els were significantly higher in patients with endometrio-
sis or hydrosalpinx compared to patients with tubal
obstruction [29]. No correlation was reported between
the follicular NO levels and follicle maturity or follicle
quality.
Some studies have demonstrated the relationship
between NO concentrations in follicular growth and pro-
grammed follicular cell death (apoptosis). Folliculogene-
sis involves the participation of both growth of the follicle
and apoptosis. Nitric oxide regulates both of these proc-
esses [21]. Sugino et al studied the role of nitric oxide in
follicular atresia and apoptosis, in patients undergoing
IVF and found that the smaller follicles had significantly
elevated percentage of apoptotic granulosa cells with
nuclear fragmentation [58]. Low concentrations of NO
may prevent apoptosis, however pathologically high con-
centrations of NO, as well as increased superoxide gener-
ation by NO synthase due to lack of arginine, may
promote cell death by peroxynitrite generation [21]. Nitric
oxide involvement in various ovarian functions has been
suggested. The presence of NO in the follicular fluid and
the expression of NO synthase in follicles and corpus
luteum have been reported [19,141,143,145].
Plasma concentration of NO was shown to increase in the
follicular phase compared with the secretory phase and
peaked at midcycle [140]. Nitric oxide elicited a positive
effect on women with poor ovarian response compared to
controlled ovarian stimulation [146]. Upregulated NO is
harmful to implantation and pregnancy among patients
with tubal factor infertility after controlled ovarian stimu-
lation [147]. Serum NO levels were elevated amongst
nonpregnant patients with tubal or peritoneal factor infer-
tility [124].
Follicular fluid NO level is not associated with maturity or
quality of oocyte and no significant differences were seen
in concentrations of NO of follicular fluid among large,
medium, or small follicle size. Higher TNF-α concentra-
tions in follicular fluid correlated with poor oocyte quality
[29]. Whereas, follicular fluid nitrite or nitrate levels were
significantly lower in follicles containing mature oocytes
that fertilized compared with those that did not [148].
Follicular NO has been reported to correlate negatively
with embryo quality and the rate of embryo cleavage
[124,147,148]. The beneficial effects of NO donors in
patients with intrauterine growth retardation (IUGR) and
inhibition of pre-term labor has been studied [149,150].
Using a nitroglycerine (NTG) patch, which is a NO donor,
did not significantly affect the final outcome in patients
undergoing in-vitro fertilization. In addition, neither pla-
cebo nor the nitroglycerine patch improved the flow
resistance in the uterine artery [22]. NO donors and ele-
vated serum NO was associated with implantation failure
resulting in decreased fertility [138].
3. Assisted reproduction
Assisted reproductive technique (ART) involves the direct
manipulation of the human oocytes, sperm or embryos
outside the body, to establish a pregnancy. A variety of
causative factors of infertility can be indications for ART,
i.e. tubal factor, endometriosis, male factor and unex-
plained infertility [151,152]. Assisted reproductive tech-
niques offer excellent opportunities to infertile couples for
achieving pregnancy. There may be multiple sources ofReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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ROS in an IVF setting including the oocytes, cumulus cell
mass, or spermatozoa used for insemination [153].
3.1 Oxidative stress and its impact on ART
The follicular fluid microenvironment has a crucial role in
determining the quality of the oocyte. This in turn impacts
the fertilization rate and the embryo quality. Oxidative
stress markers have been localized in the follicular fluid in
patients undergoing IVF/embryo transfer (ET)
[4,51,154,155]. Low intrafollicular oxygenation has been
associated with decreased oocyte developmental potential
as reflected by increasing frequency of oocyte cytoplasmic
defects, impaired cleavage and abnormal chromosomal
segregation in oocytes from poorly vascularised follicles
[156]. ROS may be responsible for causing increased
embryo fragmentation, resulting from increasing apopto-
sis [157]. Thus increasing ROS levels are not conducive to
embryo growth and result in impaired development. Cur-
rent studies are focusing on the ability of growth factors to
protect in vitro cultured embryos from the detrimental
effects of ROS such as apoptosis. These growth factors are
normally found in the fallopian tubes and endometrium.
The factors being investigated are: Insulin growth factor
(IGF)-1, and Epidermal growth factor (EGF) in mouse
embryos, which in many respects are similar to human
embryos [158].
Exogenous gonadotropin has a stimulatory effect on the
follicular content of iron, which is a potent oxidant, catal-
yses generation of free radicals in Haber-Weiss reaction.
Iron overload in thalassemia acts as a redox-active center
and there is resultant increase in the production of free
radicals [159]. Increase in free radicals was reported in fol-
licular fluid of patients with thalassemia. The spectrum of
initial hypogonadism and later gonadal failure in tha-
lassemia, results from the injury mediated by free radicals.
Increase in TAC was seen in follicular fluid of oocytes that
later were successfully fertilized. Therefore, lower total
antioxidant capacity is predictive of decreased fertilization
potential [154]. Lower levels were associated with
increased viability of the embryos until the time of
transfer, and the fertilization potential decreased with
decreasing concentrations of total antioxidants. Similarly
mean glutathione peroxidase levels were increased, in fol-
licles yielding oocytes that were subsequently fertilized
[42]. Levels of ROS were reported to be significantly lower
in patients who did not become pregnant compared with
those who became pregnant [4]. Thus intrafollicular ROS
levels may be used as a potential marker for predicting
success with IVF. Studies determining normal TAC levels
of the follicular fluid in unstimulated cycles are lacking.
In addition levels of selenium in follicular fluid of women
with unexplained infertility were lower than those in
women with tubal factor or male factor infertility [42].
Higher levels of superoxide dismutase activity were
present in fluid from follicles whose oocytes did not ferti-
lize compared with those that did [12]. These discrepan-
cies may be due to the fact that the studies measured
different parameters. The effects of follicular OS on oocyte
maturation, fertilization and pregnancy have also been
studied [51]. Patients who became pregnant following IVF
or ICSI had higher lipid peroxidation levels and TAC.
Both markers were unable to predict embryo quality.
Pregnancy rates and levels of lipid peroxidation and TAC
demonstrated a positive correlation.
OS in follicular fluid from women undergoing IVF was
inversely correlated with the women's age [160]. Using a
thermochemiluminescence assay, the slope was found to
positively correlate with maximal serum estradiol levels,
number of mature oocytes and number of cleaved
embryos and inversely with the number of gonadotropin
ampoules used. The pregnancy rate achieved was 28% and
all pregnancies occurred when the thermochemilumines-
cence amplitude was small. This is in agreement with
another study that reported minimal levels of OS were
necessary for achieving pregnancy [51]. Follicular fluid
ROS and lipid peroxidation levels may be markers for suc-
cess with IVF.
Oocyte quality is a very important determining factor in
the outcome of IVF/ET. 8-hydroxy-2-deoxyguanosine is a
reliable indicator of DNA damage caused by oxidative
stress. This compound is an indicator of OS in various
other disease processes i.e. renal carcinogenesis, and dia-
betes mellitus. Higher levels of 8 hydroxy 2-deoxyguano-
sine were associated with lower fertilization rates and
poor embryo quality [52]. Higher levels of 8-hydroxy 2-
deoxyguanosine are also seen in granulosa cells of
patients with endometriosis, and this may impair the
quality of oocytes.
Other OS markers such as thiobarbituric acid-reactive sub-
stances, conjugated dienes and lipid hydroperoxides have
been studied in the preovulatory follicular fluid [15]. No
correlation was seen between these markers and IVF out-
come (fertilization rates or biochemical pregnancies)
[15]. A potent antioxidant system may be present in the
follicular fluid as indicated by low levels of all 3
biomarkers of oxidative stress in the follicular fluid. A
recent chemiluminescence study examined the follicular
fluid obtained from patients undergoing IVF. Hydrogen
peroxide was utilized for the induction of chemilumines-
cence. The study found that a delicate balance was main-
tained by pro-oxidant/antioxidants in the follicular fluid
[161].Reproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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Smoking has been associated with prolonged and dose-
dependent adverse effects on ovarian function [162].
According to a meta-analysis, the overall value of the odds
ratio for the risk of infertility associated with smoking was
1.60 [95% confidence interval (CI) 1.34–1.91]. ARTs,
including IVF, are further shedding light on the effects
smoking has on follicular health. Intrafollicular exposure
to cotinine increases lipid peroxidation in the follicle
[155]. Carotenoids have gained attention because they are
similar to vitamin E in that they are very potent antioxi-
dants and react with ROS; the presence of carotenoids has
been demonstrated in the follicular fluid [163]. Concen-
trations of carotenoids, retinol and alpha tocopherol were
found to be significantly higher in follicular fluid than in
plasma.
Melatonin was investigated as a drug to improve oocyte
quality in patients failing to get pregnant in earlier IVF
cycles because of poor quality oocytes [164]. A significant
reduction in the number of degenerate oocytes was
reported, and the number of fertilized embryos increased.
Increased follicular concentrations of melatonin reduced
lipid peroxide concentration and may have prevented
DNA damage.
3.2 Redox and early embryo development
Physiological levels of redox may be important for embry-
ogenesis. Overproduction of ROS is detrimental for the
embryo, resulting from impaired intracellular milieu and
disturbed metabolism [17,165]. Superoxide anion,
hydrogen peroxide and hydroxyl radical, can have detri-
mental effects on the fetus. Oxidative stress can be gener-
ated by spermatozoa, leucocytes, and by events such as
sperm mediated oocyte activation and activation of the
embryonic genome [165]. The ROS generation can result
from oxidative phosphorylation occurring in the mito-
chondria. Electrons leak from the electron transport chain
at the inner mitochondrial membranes. These electrons
are transferred to the oxygen molecule, resulting in an
unpaired electron in the orbit. This leads to the generation
of the superoxide molecule. The other points of genera-
tion of ROS are the cytoplasmic NADPH-oxidase, cyto-
chrome p450 enzymes and the xanthine oxidoreductase
enzymes. Excessive OS can have deleterious effects on the
cellular milieu and can result in impaired cellular growth
in the embryo or apoptosis resulting in embryo fragmen-
tation. Thus OS mediated damage of macromolecules
plays a role in fetal embryopathies. Deficient folate levels
in the mother result in elevated homocysteine levels.
Homocysteine induced oxidative stress has been pro-
posed as a potential factor for causing apoptosis and dis-
rupting palate development and causing cleft palate
[166]. Oxidative stress mediated damage of the macro-
molecules has been proposed as a mechanism of thalido-
mide induced embryopathy and other embryopathies
[167,168].
Hyperglycemia/diabetes induced down regulation of
cycloxygenase-2 gene expression in the embryo results in
low PGE2 levels and diabetic embryopathy [169]. The pro-
tective role of the enzyme G6PD (Glucose 6-phophate
dehydrogenase) against oxidative stress has been demon-
strated in an animal study and embryopathies were pre-
vented by protecting the embryos against oxidative stress
[170].
3.3 Effect of oxygen concentration on in-vitro embryo development
Early embryo development in mammals occurs from fer-
tilization through differentiation of principal organ sys-
tems in a low oxygen environment [168]. A marginal
improvement in preimplantation embryonic viability has
been reported under low oxygen concentrations in
patients undergoing IVF and ICSI [171]. Lower concentra-
tions of oxygen in in-vitro culture of porcine embryos
decreased the H2O2 content and resulted in reduced DNA
fragmentation, which thereby improved developmental
ability [172]. The higher oxygen concentration of 20%
have been associated with lower developmental compe-
tence. Accelerated development was seen under low (5%)
oxygen concentrations.
3.4 Role of ROS in IVF media
ROS may be generated endogenously or exogenously, but
either way it can affect the oocyte and embryo. IVF culture
media may be the exogenous site of ROS generation
affecting the oocytes and the preimplantation embryo.
There are some specific events in embryo development
associated with a change in the redox state. It has been
suggested that redox may have a causative role in sperm
mediated oocyte activation, embryonic genome activation
and embryonic hatching from the zona pellucida [165].
Higher day 1 ROS levels in culture media were associated
with delayed embryonic development, high fragmenta-
tion and development of morphologically abnormal blas-
tocysts after prolonged culture. A significant correlation
was reported between increased ROS levels in Day1 cul-
ture media and lower fertilization rates in patients under-
going ICSI [153]. Lower ROS levels were associated with
higher fertilization rates, indicating the physiological rel-
evance of low levels of ROS.
Incubation of poor quality embryos was associated with a
decline in TAC in the preimplantation embryo culture
medium after 24 hours incubation. Poor quality embryos
may be associated with increased generation of ROS
[173]. HEPES [(2-hydroxyethyl) piperazine-1-ethanesul-
fonic acid] was found to be the most potent protector
compared to human tubal fluid media and polyvinyl alco-
hol against DNA damage occurring in spermatozoa, asReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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determined by plasmid relaxation assay which measures
the plasmid DNA damage [174]. IVF media supplemented
with human serum albumin (10 mgm/mL), glucose (2.78
Mmol), 1% polyvinyl alcohol, 5% polyvinylpyrrolidone,
sucrose (100 mM), 60% Percoll, human tubal fluid,
human tubal fluid media, catalase (1 and 10 IU), and
HEPES (21 mMol) scavenge ROS and confer protection
from DNA damage [174].
3.5 Strategies to overcome oxidative stress in infertility/ART
Considerable interest has been generated in the use of
antioxidants to overcome the adverse and pathological
results of OS. Oxidative stress leads to luteal regression,
[43] resulting in a lack of luteal support to a pregnancy
[33]. OS can damage oocytes in developing follicles,
oocytes and spermatozoa in the peritoneal cavity, or
embryo in fallopian tube [17,153] or through redox (pro-
oxidant and antioxidant) imbalance. OS can be overcome
by reducing generation of ROS or increasing the amounts
of antioxidants available. The literature contains studies
that used nutritional supplements and antioxidants like
vitamin C supplementation to protect against ROS and
OS. However, there is lack of consensus on the type and
dosage of antioxidants to be used. Clinical evidence on
the benefits of antioxidant supplementation is equivocal.
Current evidence supports the use of systemic antioxi-
dants for management of selected cases of male infertility
[175]. Randomised controlled trials investigating antioxi-
dants in female infertility are few and lack power because
of the small patient numbers. In a recent randomized con-
trolled, multi-center study, the effect of vitamin C supple-
mentation (750 mg/day) in patients with a luteal phase
defect was reported; pregnancy rates were higher in the
treatment group than in the controls [176]. Similarly, con-
centrations of antioxidants were found to be significantly
lower in women with a history of recurrent miscarriages
and luteal phase defects than in healthy women [177].
Vitamin C concentrations were higher in the follicular
fluid of patients supplemented with vitamin C than that
of the controls. Pregnancy rate was higher in the supple-
mented group than in the control group although the dif-
ference was not statistically significant [178].
In a double blinded, placebo-controlled pilot study, the
impact of a nutritional supplement containing vitamin E,
iron, zinc, selenium, L-arginine was examined [179]. The
mean mid-luteal progesterone levels increased from 8.2
ng/mL to 12.8 ng/mL, (p = 0.08), and the patients had a
significant increase in ovulation and pregnancy rates
(33% pregnant, p < 0.01) [179]. In a study looking at
short-term supplementation with high doses of ascorbic
acid during the luteal phase in IVF, the clinical pregnancy
rate and implantation rate did not improve [180]. There is
lack of consensus on antioxidant supplementation in idi-
opathic infertility and randomized controlled trials need
to be designed with sufficient power and patient numbers
to investigate this issue.
Fertilization and embryo development in vivo occurs in
an environment of low oxygen tension [168]. During
ART, it is important to avoid conditions that promote
ROS generation and expose gametes and embryos to ROS.
During culture, low oxygen tension is more effective at
improving the implantation and pregnancy rate than
higher oxygen tension [181]. Similarly, higher implanta-
tion and clinical pregnancy rates are reported when anti-
oxidant supplemented media is used rather than standard
media without antioxidants. Metal ions can sometimes
result in the production of oxidants. Metal ions can also
increase the production of ROS directly through the
Haber-Weiss reaction. It may be useful to add metal ion
chelating agents to the culture media to decrease the pro-
duction of oxidants [181].
Amino acids added to the IVF media also have antioxidant
properties. Adding ascorbate during cryopreservation
reduces hydrogen peroxide levels and thus the oxidative
distress in mammalian embryos [182]. As a consequence,
the embryo development improved with enhanced blast-
ocyst development rates. A significant negative associa-
tion has been reported between duration of smoking and
fertilization rates in IVF procedures. Eliminating the
smoking factor would help improve fertility and ART out-
comes [178]. Because a history of smoking is associated
with high concentrations of OS, in-vivo antioxidants can
be recommended in infertile women who smoke [155].
Follicular vascularity determines the intrafollicular oxy-
gen content and the developmental potential of the
oocyte [156,183]. Intrafollicular hypoxia results in chro-
mosomal segregation disorders and deleterious mosai-
cisms in the embryo. Sildenafil, an inhibitor of
phosphodiesterase enzyme, prevents the breakdown of
cGMP and potentiates the effects of NO on vascular
smooth muscle. Vaginal Sildenafil and L-arginine have
been investigated for their potential to improve intrafol-
licular blood flow by potentiating the actions of NO on
vascular smooth muscle. It augments the effect of NO in
inducing vasodilatation and thus improving uterine
blood flow. A recent study reported that Sildenafil,
administered on day 3 of the menstrual cycle, appeared
effective in improving uterine artery blood flow and
endometrial development [184]. The same group in a
subsequent cohort of 105 patients with infertility and pre-
vious failures at IVF were able to achieve higher implanta-
tion and pregnancy rates with vaginal Sildenafil [185]
Oral L-arginine supplementation in poor responder
patients, during controlled ovarian stimulation mayReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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improve ovarian response, endometrial receptivity and
pregnancy rate by increasing the flow around the follicles,
and uterine flow [146]. Follicular fluid concentrations of
nitrite/nitrate inversely correlated with embryo quality.
Although the embryo quality was poor, L-arginine supple-
mentation in normally responding patients resulted in
higher follicular fluid arginine levels compared to the
poor responders and increased follicular recruitment
[147]. NO derivatives in higher doses in follicular fluid
may cause cytostatic and cytotoxic effects and may have
detrimental consequences on embryo quality, implanta-
tion and pregnancy rate.
Mechanical removal of ROS in IVF/ET has been examined
[186]. Cumulus oophorus rinsing is performed to over-
come the deleterious effects of ROS in patients with ovar-
ian endometriosis [186]. ROS has deleterious effects on
both the oocyte and the embryo quality. The deleterious
effects of TNF-α cytokines and reactive oxygen species,
which were increased in the peritoneal fluid of patients
with endometriosis and unexplained infertility, were pre-
vented, by the rinsing procedure.
3.6 Critical review of OS, ovary and ART
A comprehensive review of the published literature
reveals that the role of oxidative stress is controversial due
to the differences in the nature of materials examined, (i.e.
follicular fluid, embryos, and culture mediums). We can
conclude the number of articles on oxidative stress in the
last 5 years have significantly increased compared to the
previous 5 years indicating that more studies are being
conducted to understand the role of oxidative stress in
female reproduction. The effects of ROS studied and its
ability to influence female reproduction have been stud-
ied on various endpoints in terms of the oocyte, fertiliza-
tion, embryo and pregnancy. Different markers of
oxidative stress are reported in various studies and the
sensitivity and specifity of the various biomarkers are not
known. While some research is focused on studying the
antioxidant capacity others focus on studying and deter-
mining the levels of oxidative stress markers. Also, there
has been an assumption in the studies measuring the
amount and type of antioxidants that there is an inverse
correlation between oxidative stress markers and
antioxidants. These studies have also variations because
some have measured the total antioxidant capacity and
some have measured individual enzymes like superoxide
dismutase. Further studies need to be designed to validate
the results of the earlier studies, with elimination of vari-
ous factors leading to bias. Eliminating the bias will make
the comparison of different studies acceptable and pro-
vide support to the evidence based approach. The biomar-
kers of oxidative stress that are studied should be similar
across different studies to make the results comparable.
Prospective, randomized controlled trials with stringent
inclusion criteria are needed to determine the effects of
antioxidants in overcoming redox in infertility patients.
4. Age related fertility decline, Menopause and ROS
There is an age related decline in the number and quality
of follicles in females. ROS may damage the oocytes
[187]. The age related decline in oocyte quality also results
in increased incidence of congenital anomalies in chil-
dren. The ageing of the oocytes affects many biochemical
pathways which have a deleterious effect on pre- and post
implantation development of the embryo [188]. The pre-
and postovulatory ageing of the oocytes have also been
associated with congenital anomalies, behavorial altera-
tions, and learning disabilities in later life and constitu-
tional diseases such as diabetes mellitus, and
schizophrenia. Oxidative stress occurs at menopause
because of loss of estrogens, which have antioxidant effect
on low-density lipoproteins. Estrogens confer cardiopro-
tection by lowering protein oxidation and antioxidant
properties [189]. Diminished antioxidant defense is asso-
ciated with osteoporosis in post-menopause. Modulation
of the estrogen receptors α and β has been reported to be
effected in vitro by oxidative stress [190].
5. Oxidative stress and pregnancy
5.1 Oxidative stress and pre-eclampsia
Pre-eclampsia is associated with severe maternal and fetal
morbidity and mortality [191]. Overall pre-eclampsia
complicates 5% of all pregnancies and 11% of all first
pregnancies. Recent evidence suggests the role of oxidative
stress in pre-eclampsia. There is a reduced antioxidant
response inpatients with pre-eclampsia [192,193] and
reduced levels of antioxidant nutrients [194] and
increased lipid peroxidation [45,194].
5.2 Placental oxidative stress and Pre-eclampsia
Incomplete trophoblast invasion leads to failure of con-
version of thick walled tortous spiral arteries to low resist-
ance flaccid sinusoidal vessels [195,59]. The incomplete
invasion results in impaired placental perfusion. The
hypoxia/reperfusion injury leads to increased expression
of xanthine oxidase and NADP (H) oxidase and resultant
increased generation of superoxide anion. The increased
generation of pro-oxidants tilts the balance in favor of oxi-
dative stress, which results in increased lipid peroxidation.
Biomarkers of lipid peroxidation are elevated in the pla-
centa [45,60].
5.3 Interventions to overcome oxidative stress in pre-eclampsia
There is currently no accepted method of prevention of
pre-eclampsia. Antioxidants vitamin C and vitamin E have
been studied in some trials for preventing pre-eclampsia.
Early intervention at 16–22 weeks of pregnancy with sup-
plementation of vitamin E and C resulted in significant
reduction of pre-eclampsia in the supplemented groupReproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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[196]. Supplementation in women with established pre-
eclampsia did not result in any benefit [197]. Recent
report of a randomized trial failed to find beneficial effects
of vitamin C and E supplementation in preventing preec-
lampsia [198].
5.4 Redox and miscarriage
Human placenta is classified as hemomonochorial.
Maternal blood directly bathes the fetal trophoblast.
Establishment of the maternal placental circulation is
influenced by the trophoblastic invasion. Extravillous tro-
phoblastic invasion transforms the small caliber high
resistance spiral arteries into large caliber, low resistance,
and high capacitance uteroplacental arteries. Abnormal
placentation has been implicated in the pathogenesis of
pre-eclampsia and miscarriage [199]. Pre-eclampsia is
unique to human species and miscarriage is very rare in
other species [200]. Abnormal placentation leads to pla-
cental oxidative stress with resultant detrimental effects
on the syncitiotrophoblast and it has been proposed as a
mechanism involved in the etiopathogenesis of abortion.
A sharp peak in the expression of the markers of oxidative
stress in the trophoblast was detected in normal pregnan-
cies and this oxidative burst if excessive was speculated to
be a cause of early pregnancy loss [168].
The etiology of recurrent pregnancy loss remains unclear
and is a scientific challenge. Oxidative stress may have a
role in the etiology of recurrent pregnancy loss with no
known etiology. Glutathione and glutathione transferase
family of enzymes have been investigated in patients who
experience recurrent abortions [201,202]. Glutathione
and glutathione peroxidase are both antioxidants that
neutralize the free radicals and lipid peroxides to main-
tain the intracellular homeostasis and redox balance.
The etiology of recurrent pregnancy loss is multifactorial
and involves genetic and environmental factors [203]. In
a large case controlled study, gene polymorphisms of
enzymes of the glutathione family, glutathione S-trans-
ferase class mu (GSTM1) were studied. Elevated risk of
recurrent pregnancy loss was found to be associated with
the GSTM1 genotype null polymorphism, in patients with
recurrent pregnancy loss. Elevated glutathione levels in
pregnant patients with history of recurrent pregnancy loss
were associated with poor outcomes (i.e. abortion) [201].
5.5 Term labor and the role of oxidative stress
There is increased generation of free radicals superoxide
and nitric oxide in pregnancy, which results in oxidative
stress [35]. Term labor induces increased lipid peroxida-
tion, as evidenced by increased levels of the biomarker,
malondialdehyde [37]. In a case controlled study, the
serum levels of hydroperoxides were higher in patients in
labor, compared to the controls, who were not in labor
[36]. Term labor was demonstrated to cause an up regula-
tion of the antioxidant reserve in the fetal compartment
[66]. The role of oxidative stress in initiation of labor is
not known.
F2-isoprostanes, reliable biomarkers of oxidative stress
were shown to be significantly elevated in plasma of
neonates compared to adults [204]. The study also dem-
onstrated an inverse correlation between gestational age
and plasma isoprostane levels.
5.6 Interventions to overcome oxidative stress during pregnancy
Based on the understanding of the pathophysiological
role of NO in the female reproductive tract, NO donors
have been studied for cervical ripening at term. In a rand-
omized controlled study, vaginal administration of iso-
sorbide dinitrate induced cervical ripening at term [205].
Oxidative stress leads to focal collagen damage in the fetal
membranes and result in preterm labor [39,206]. Antioxi-
dant supplementation has been investigated in preterm
labor and pre-eclampsia for beneficial effects [196,207].
Another randomized double-blinded placebo controlled
trial initiated in 2003 will examine women with type-1
diabetes. These women were randomized to receive anti-
oxidant supplementation with vitamin C and vitamin E.
Benefits of antioxidant supplementation will be investi-
gated in patients with type-1 diabetes and the incidence of
pre-eclampsia in this group of patients will be studied
[208]. In addition the secondary outcomes of birth weight
centile and the endothelial activation indicated by PAI-1/
PAI-2 (plasminogen activator-1/plasminogen activator-2)
ratio will also be studied [208].
6. Future perspectives in antioxidant therapy
Antioxidants prevent the actions of the free radicals of oxi-
dizing the substrate. Studies conducted in humans aimed
at delineating the association of TAC content of food with
incidence of chronic diseases [209]. The nutrients that are
being studied for their effects on chronic diseases are vita-
min C, Vitamin E, carotenoids and selenium. Pregnant
women with HIV infection, selenium deficiency or micro-
nutrient deficiencies like vitamin C and vitamin A, were
found to have adverse clinical outcomes in large prospec-
tive studies [210,211]. There is increasing argument for
increasing the selenium intake in these patients. There is
emerging enthusiasm in the use of antioxidants, natural
or synthetic. Small molecules that mimic antioxidant
enzymes are the new tools being developed in the antioxi-
dant armamentarium [212]. These are cell membrane per-
meable unlike the natural superoxide dismutase.
Antioxidants targeting cellular organelles like mitochon-
dria are also being investigated. Gene polymorphisms of
the glutathione S-transferase family and myeloperoxides
and their association with endometriosis, is an area of
recent interest, which is promising [26].Reproductive Biology and Endocrinology 2005, 3:28 http://www.rbej.com/content/3/1/28
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7. Conclusion
The literature provides some evidence of oxidative stress
influencing the entire reproductive span of a woman, even
the menopausal years. OS plays a role in multiple physio-
logical processes from oocyte maturation to fertilization
and embryo development. There is burgeoning literature
on the involvement of OS in the pathoysiology of infertil-
ity, assisted fertility and female reproduction. Infertility is
a problem with a large magnitude. In this review we
attempted to examine the various causes of female infer-
tility and the role of OS in various etiologies of infertility.
OS can arise as result of excessive production of free radi-
cals and/or impaired antioxidant defense mechanism. An
increasing number of published studies have pointed
towards increased importance of the role of OS in female
reproduction. Clearly, we have much to learn, but what
we do know is that the role of OS in female reproduction
cannot be underestimated. There is evidence that OS plays
a role in conditions such as abortions, pre-eclampsia,
hydatidiform mole, fetal embryopathies, preterm labor
and pre-eclampsia and gestational diabetes, which lead to
an immense burden of maternal and fetal morbidity and
mortality. The review addresses the issue that both NOS
and ROS species can lead to infertility problems and a
spectrum of female reproductive disorders. We emphasize
that free radicals have important physiological functions
in the female reproductive tract as well as excessive free
radicals precipitate female reproductive tract pathologies.
Reference values for ROS and NOS, minimum safe con-
centrations or physiologically beneficial concentrations
have yet not been defined. Patients should be assessed
according to the etiological factors and analyzed sepa-
rately. Most of the published studies on oxidative stress
are either observational or case control studies. Newer
studies should be designed with more patient numbers;
similar outcome parameters and uniform study popula-
tions so that results can be more easily compared. Meas-
urement of OS in vivo is controversial. The sensitivity and
specificity of various oxidative stress markers is not
known. Measurement of biomarkers of OS is subject to
interlaboratory variations, and interobserver differences.
A uniform method with comprehensive assessment of the
OS biomarkers should be used so that the results can be
compared across the studies. Treatment strategies of anti-
oxidant supplementation, directed toward reducing OS
need to be investigated in randomized controlled trials.
Antioxidants maybe advised when specific etiology can-
not be identified as in idiopathic infertility as there is no
other evidence based treatment for idiopathic infertility
and reports indicate the presence of OS. Strategies to over-
come OS in-vitro conditions and balancing between in
vivo and in vitro environments can be utilized in ART, to
successfully treat infertility. Interventions for overcoming
oxidative stress in conditions such as abortions, preec-
lampsia, preterm labor and gestational diabetes and intra-
uterine growth retardation are still investigational with
various randomized controlled trials in progress.
Legend
Reprinted from an article in Reproductive BioMedicine
Online by Agarwal and Allamaneni, 2004, with permis-
sion from Reproductive Healthcare Ltd [33].
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